Statins for primary pre- vention of cardiovascular events and mortality in older men. J Am Geriatr Soc. 2017;65:2362 8. S4.4.4.1-6. Mihaylova B, Emberson J, Blackwell L, et al. The effects of lower- ing LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 ran- domised trials. Lancet. 2012;380:581 90. S4.4.4.1-7. Savarese G, Gotto AM Jr, Paolillo S, et al. Benefits of statins in elderly subjects without established cardiovascular disease: a meta-analysis. J Am Coll Cardiol. 2013;62:2090 9. S4.4.4.1-8. Teng M, Lin L, Zhao YJ, et al. Statins for primary prevention of cardiovascular disease in elderly patients: systematic review and meta-analysis. Drugs Aging. 2015;32:649 61. S4.4.4.1-9. Kutner JS, Blatchford PJ, Taylor DH Jr, et al. Safety and benefit of discontinuing statin therapy in the setting of advanced, life- limiting illness: a randomized clinical trial. JAMA Intern Med. 2015;175:691 700. S4.4.4.1-10. Mahabadi AA, Mohlenkamp S, Lehmann N, et al. CAC score improves coronary and CV risk assessment above statin indication by ESC and AHA/ACC primary prevention guidelines. J Am Coll Cardiol Img. 2017;10:143 53. S4.4.4.1-11. Mortensen MB, Fuster V, Muntendam P, et al. A simple disease- guided approach to personalize ACC/AHA-recommended statin allocation in elderly people: the BioImage study. J Am Coll Cardiol. 2016;68:881 91. S4.4.4.1-12. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360:1623 30. S4.4.4.1-13. Mortensen MB, Falk E. Primary prevention with statins in the elderly. J Am Coll Cardiol. 2018;71:85 94. S4.4.4.1-14. Bell SP, Orr NM, Dodson JA, et al. What to expect from the evolving field of geriatric cardiology. J Am Coll Cardiol. 2015;66:1286 99. S4.4.4.1-15. Fleg JL, Forman DE, Berra K, et al. 